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To investigate the molecular role of the tobacco mosaic tobamovirus (TMV) coat protein (CP) in conferring cross-
protection, a potato X potexvirus (PVX) vector (S. Chapman, Plant J. 2, 549–557, 1992) was used to systemically express a set
of TMV mutant CPs in Nicotiana benthamiana prior to challenge inoculation with TMV. PVX-expressed wild-type TMV CP
delayed TMV accumulation for up to 2 weeks compared to unprotected plants or plants preinfected with the unmodified PVX
vector. Similar delays in TMV accumulation were obtained using TMV CPs that were deficient in virion formation but
competent to assemble into helical aggregates. In contrast, TMV CPs that were incapable of helical aggregation or unable
to bind viral RNA did not delay the accumulation of TMV. Furthermore, TMV CPs with enhanced intersubunit interactions that
favor helical aggregation produced significantly greater delays in the accumulation of challenge TMV than obtained from the
wild-type CP. Thus the capabilities of TMV CP to interact with viral RNA and self-associate in a helical fashion appear to be
essential to its ability to confer protection. Taken together, these findings support a model for CP-mediated resistance in
which the protecting CP recoats the challenge virus RNA as it disassembles. © 1998 Academic Press
INTRODUCTION
It has long been known that the activity of one plant
virus can prevent or delay the infection of a subsequent
virus (McKinney, 1929). This phenomenon, termed cross-
protection, occurs between closely related viruses. In
addition, the virus conferring the protection (the protect-
ing virus) must be established prior to inoculation with
the second virus (the challenge virus). Several mecha-
nisms have been proposed to account for the observed
protection, including (1) the protecting virus occupies or
depletes host metabolites and/or structures needed by
the challenge virus to establish an infection, (2) RNA from
the protecting strain hybridizes with nascent RNA of the
challenge virus, (3) the coat protein (CP) of the protecting
virus inhibits uncoating of the challenge virus genome,
(4) the presence of the protecting virus blocks systemic
movement of the challenge virus, and (5) replication of
the protecting virus activates a host defense mechanism
that targets the challenge virus RNA for degradation
(Sherwood and Fulton, 1982; Palukaitis and Zaitlin, 1984;
Dodds et al., 1985; Ponz and Bruening, 1986; Sherwood,
1987; Angell and Baulcombe, 1997). Unfortunately, the
actual contributions of each of these mechanisms in
conferring cross-protection remains largely unknown.
Within the tobamovirus group, the involvement of the
viral CP in cross-protection has been investigated. In
particular, the protection conferred by tobacco mosaic
tobamovirus (TMV) can be overcome by challenge inoc-
ulation with infectious uncoated RNA (Sherwood and
Fulton, 1982). Cross-protection also does not occur in the
dark green mosaic areas of systemically infected tissue
where the accumulation of the protecting virus is low
(Fulton, 1951; Sherwood and Fulton, 1982; de Zoeten and
Gaard, 1984). Additionally, a TMV mutant defective in the
ability to produce CP did not confer protection against
challenge inoculations (Sherwood, 1987). Based on
these and similar findings it has been proposed that
cross-protection between TMV strains is the result of the
CP from the protecting virus inhibiting the disassembly of
the challenge virus (de Zoeten and Fulton 1975; Sher-
wood and Fulton, 1982). However, evidence contradicting
CP’s role in cross-protection has also been presented.
For example, Gerber and Sarkar (1989) determined that a
TMV mutant incapable of producing CP was able to
confer protection against TMV in Samsun tobacco. Fur-
thermore, Zaitlin (1976) demonstrated that a TMV mutant
producing an insoluble defective CP still functioned to
confer protection against challenge inoculations. Thus
questions have remained as to the precise role CP plays
in conferring protection.
Cross-protection also forms the basis of pathogen-
derived resistance in transgenic plants. In this strategy,
the integration and expression of specific viral genes
results in measurable levels of protection from challenge
virus infections (Sanford and Johnston, 1985). Presum-
ably, the transgene-expressed viral components interfere
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with the life cycle of the challenge virus via mechanisms
similar to those proposed for cross-protection. One
transgenic strategy that has proven particularly success-
ful at conferring useful levels of resistance is the incor-
poration and expression of viral CP genes. This ap-
proach, termed CP-mediated resistance (CPMR), has
been demonstrated in a number of plant virus systems,
including TMV (Powell-Abel et al., 1986; Fitchen and
Beachy, 1993). The characteristics of TMV CPMR are
similar to those of TMV cross-protection and include a
requirement for the expression of CP and the ability of
unencapsidated viral RNA to overcome the resistance
(Powell et al., 1990; Nelson et al., 1987). Based on these
and other findings, Register et al. (1989) proposed that
transgene-derived CP acts to prevent the disassembly of
the challenge virus either directly by recoating the chal-
lenge virus RNA as it disassembles or through the oc-
cupation of a host site required for virus disassembly.
More recently, Bendahmane et al. (1997) demonstrated
that the ability of TMV CP to form ordered aggregates
correlates with the level of CPMR, suggesting that proper
CP aggregation is essential for conferring protection.
Investigating the mechanism behind both cross-pro-
tection and CPMR has been complicated by several
factors. For example, within a virus infection, it is difficult
to separate the protecting effects of one virus component
from those contributed by another. One way around this
problem has been to create transgenic plants that ex-
press individual virus genes. However, transgenic plants
require an extensive amount of time to create and test,
making it difficult to rapidly screen multiple constructs for
the ability to confer protection. In addition, variations
between transgenic lines expressing the same con-
struct, numbers, and positions of integrated transgenes
and gene silencing can interfere with the interpretation
of the data. To avoid these problems we have utilized a
heterologous potato X potexvirus vector (PVX2C2S) as a
novel and rapid method to express a set mutant TMV
CPs in Nicotiana benthamiana.
PVX vector-expressed TMV CP confers protection
against TMV challenge inoculation in a manner similar to
both cross-protection and CPMR in that it requires the
expression of CP, is limited to closely related strains of
TMV, and is overcome by unencapsidated viral RNA
(Culver, 1996). For experiments in this study, the known
three-dimensional structure of the TMV CP was used to
identify residues involved in specific CP–CP and CP–
RNA interactions (Namba et al., 1989). TMV CP has a
molecular weight of 17.5 kDa and contains a high pro-
portion of secondary structure (Fig. 1). Depending upon
conditions, TMV CP forms a variety of aggregates. These
include a 20S aggregate, which has been identified as
either a two-layered disk having 17 subunits in each
layer (Durham et al., 1971; Butler et al., 1992) or a short
helix containing about 38 subunits in a little over two
turns (Correia et al., 1985; Rhagavendra et al., 1988). The
20S aggregate is required for nucleation with the viral
RNA and is also involved in virion elongation (Butler et
al., 1977; Lebeurier et al., 1977). TMV virions are com-
posed of approximately 2130 CP subunits arranged in a
right-handed helix about a single strand of plus sense
RNA. Within both aggregates of CP and TMV virions
there are extensive intermolecular interactions that oc-
cur in both the lateral and axial directions as well as
between the CP and RNA. Thus CP structural changes
brought about by specific amino-acid substitutions can
dramatically affect both the tertiary and quaternary struc-
tures of CP as well as its ability to bind viral RNA.
Site-directed mutagenesis was used to alter the iden-
tified residues in such a way as to disrupt the targeted
CP interactions. The effects of these substitutions on the
ability of the mutant TMV CPs to form ordered aggre-
gates and virions were then correlated with their ability
to confer protection against TMV challenge inoculation
when expressed by the PVX vector. Results demon-
strated that protection was dependent upon the ability of
CP to self-associate in a helical fashion as well as bind
viral RNA. These findings indicate that the protecting CP
interacts directly with the disassembling virion to confer
protection.
FIG. 1. Computer graphic representations of the structure of a single
CP subunit and the 59 end of the TMV virion. (a) Ribbon representation
of the a-carbon backbone of a single TMV subunit. The four a-helices
are labeled LS (left slewed), RS (right slewed), LR (left radial), and RR
(right radial). The inner loop connects the LR and RR helices, and a
short loop connects LS and RS helices. The RNA binding site is formed
by residues from both loops and the LR helix. The N and C termini are
at the outer radius of the virus. (b) Two virion turns of CP subunits,
shown in ribbon form, along with an additional turn of free RNA, shown
in space-filling form.
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RESULTS
TMV CP constructs
The mutant CPs, expressed during TMV replication,
were initially examined for their effects on virus function
and their ability to form virion-like structures. The rapid
systemic movement of wild-type TMV in N. tabacum is, in
part, due to the ability of the virus to form functional
virions (Dawson et al., 1988). However, none of the TMV
constructs expressing the mutant CPs used in this study
was able to travel systemically in N. tabacum. In addition,
extracts from plants infected with these TMV constructs
were at best poorly infectious as compared to extracts
from wild-type infected plants (Table 1). Electron micros-
copy studies of mutant-infected tissues also demon-
strated that none of the TMV CP constructs produced
wild-type length virions (Table 1; Fig 2).
Quantifying and comparing levels of CP derived
protection
N. benthamiana plants infected with the unmodified
PVX2C2S vector or PVX constructs that contained different
TMV CP open reading frames (ORF) exhibited similar mild
mosaic symptoms on upper noninoculated leaves within
8–10 days postinoculation (d p.i.). TMV CP expression in the
first two fully expanded leaves to display systemic PVX
symptoms were subsequently examined by Western immu-
noblotting. Levels of TMV CP in these leaves were consis-
tently estimated to range between 0.3 and 1.7% of the total
extracted leaf protein (Fig. 3). By comparison, CP expres-
sion in TMV-infected protoplasts and transgenic plants dis-
playing CPMR has been estimated at 12 and 0.1% of the
total extracted protein, respectively (Paterson and Knight,
1975; Powell-Abel et al., 1986).
Previous studies have demonstrated some instability for
foreign ORFs, including the TMV CP ORF, inserted into the
PVX2C2S vector (Chapman et al., 1992; Culver, 1996). To
avert this problem, all protecting PVX infections were initi-
ated from infectious RNA transcribed from cDNA clones. In
addition, TMV challenge inoculations were done only on
the first two fully expanded leaves of each plant to display
a mosaic PVX symptom and only then after Western immu-
noblotting showed TMV CP accumulations of at least 0.3%
of total extracted protein in these leaves.
In contrast to the mild mosaic symptoms produced by
PVX in N. benthamiana, TMV induces systemic necrosis
within 3 d p.i. This necrosis spreads rapidly within the
vascular tissues and causes plant death within 5–7 d p.i.
(Culver, 1996). Thus TMV-induced necrosis provides an
ideal marker for the development of a TMV infection. The
accumulation of TMV in challenge inoculated leaves can
also be easily determined at various time points by local
lesion assay on N. tabacum cv. Xanthi-nc, a local lesion
host for TMV but not for PVX. Thus the appearance of
necrosis and the accumulation of TMV over time can be
used as measures for the relative levels of protection
conferred by each mutant CP.
Protection conferred by mutant CPs disrupted in
intrasubunit interactions
CP substitutions F48S and R71L were created to dis-
rupt specific intramolecular interactions within a single
TABLE 1
Effects of CP Amino Acid Substitutions on TMV
Coat protein
substitutionsa Positionb EMc
Rod lengthd
(nm) Infectivitye
Wild-type — Full-length virions 300 6 29 1111
N29 D LS helix Helical rods 88 6 37 2
N33D LS helix Helical rods 118 6 61 2
Q34R Short loop Helical rods 174 6 86 2
F48S RS helix No aggregates ND 2
R71L b sheet No aggregates ND 2
D88I RR helix Disks/stacked disks ND 2
R92Q Inner loop Disks/short helices ND 2
D116A LR helix Helical rods 94 6 41 2
R122A LR helix No aggregates ND 2
I133P LR helix No aggregates ND 2
E50Q/D77N RS helix Long rods 940 6 470 1
E95Q/E97Q/D109N Inner loop Long rods 660 6 230 1
a Wild-type TMV and substituted CP residues.
b Locations of the substituted residues within the CP three-dimensional structure.
c Aggregate structures observed by electron microscopy.
d Length 6 standard deviation averaged from 50 rods. ND, not determined.
e Infectivity determined by local lesion assay. TMV mutant infected tissue, 0.1 g, was pulverized in 10mM phosphate buffer, pH 7.3, and used to
mechanically inoculate leaves of N. tabacum cv Xanthi-nc. 1111, .500 lesions per assay; 1, ,50 lesions per assay; 2, no lesions.
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CP subunit. Residue F48 makes up part of the hydropho-
bic interior of the protein core, acting to stabilize the
alignment of the four helices (Fig. 4). Substitution F48S
would be predicted to disrupt the side chain packing and
hydrophobic nature of this region and interfere with the
ability of the four helices to associate. Substitution R71L
would expose a large hydrophobic side chain to the
solvent in the native conformation (Table 1; Fig. 4). Rather
than tolerate this thermodynamically unfavorable state,
the protein probably misfolds in some manner to bury the
L71. TMV constructs F48S and R71L produced no or-
dered CP aggregates as determined by electron micros-
copy (Table 1; Fig. 2). Thus substitutions F48S and R71L
sufficiently disrupted CP tertiary structure to prevent its
ordered aggregation. PVX expression of TMV CP F48S
and R71L provided no significant level of protection com-
pared to the unmodified vector (Figs. 5 and 6).
Effects of intersubunit interactions on the ability of
CP to confer protection
Six TMV CP substitutions were created to disrupt spe-
cific intersubunit interactions. Two of these substitutions
were created at residues N29 and N33, located on the
surface of the left slewed (LS) helix, and a third at residue
Q34, which forms part of the hairpin loop joining the left
and right slewed a-helices (Fig. 4). Substitutions N29D
and N33D were designed to preserve side chain hydro-
gen bonding patterns and hydrophobic interactions
while introducing a negative charge into the axial inter-
subunit interface. Substitution Q34R would be predicted
to alter the charge along the short hairpin loop and
disrupt intersubunit contacts with residues Q45, F87, and
D88 from laterally adjacent subunits. Leaf tissue infected
with TMV constructs N29D, N33D, or Q34R all showed
FIG. 2. Electron microscopy of wild-type and mutant TMV virions/aggregates in leaf tissues of infected N. tabacum cv Xanthi plants. (A) Wild-type
TMV U1, (B) TMV CP E50Q/D77N, (C) TMV CP Q34R, (D) TMV CP D88I (inset shows the predominant disk aggregates observed for this mutant), (E)
TMV CP F48S, (F) TMV CP D116A. Bars represent 300 nm.
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the presence of virion-like helical rods that were signif-
icantly shorter in length than those of the wild-type virus
(Table 1; Fig 2). Thus these mutations only partially dis-
rupted the ability of CP to aggregate. PVX constructs
expressing N29D, N33D, or Q34R CPs conferred levels of
protection that were similar to that conferred by wild-type
TMV CP (Fig. 5).
Hydrophobic interactions contribute significantly to the
intersubunit stability of TMV CP. I133 is located on the
surface of the RR helix and makes direct lateral contacts
with Y72 of the adjacent subunit (Fig. 4). Substitution
I133P would be predicted to disrupt this intersubunit
interaction. In addition, the introduction of a proline at
this position would block the hydrogen bonding pattern
within the LR helix. This disruption would affect both
tertiary and quaternary CP structure. TMV construct
I133P produced no visible ordered aggregate of CP as
determined by electron microscopy (Table 1). The PVX
expression of I133P CP resulted in no significant level of
protection (Fig. 5).
There is an extensive intersubunit salt-bridge system
that functions to stabilize subunits both within and be-
tween CP layers in the virion. Residues D88 and R122
form a lateral intersubunit salt bridge in both the virion
and disk aggregates (Fig. 4). Substitutions D88I and
R122A were designed to disrupt this salt bridge from
either side of a subunit. TMV construct R122A produced
no ordered aggregates by electron microscopy, while
TMV D88I produced primarily open disks that occasion-
ally were found to stack in a nonhelical fashion (Table 1;
Fig. 2). This difference in the aggregating abilities of the
two mutant CPs may be the result of local structural
changes introduced by the different side chains. Plants
preinfected with PVX constructs expressing TMV CP
D88I or R122A had no significant ability to resist TMV
challenge inoculations (Fig. 5).
CP-RNA interactions are required for protection
The inner loop of the TMV CP, connecting the left
radial (LR) and right radial (RR) helices, contains many of
the residues involved in RNA binding. Within the loop,
FIG. 3. Western immunoblot detection of TMV CP expressed from the
PVX vector in N. benthamiana. Lane 1, 0.3 mg of purified TMV CP; lane
2, uninfected tissue; lane 3, infected with the unmodified PVX2C2S,
lanes 4–16, infected with PVX constructs expressing TMV wild-type,
E50Q/D77N, E95Q/E97Q/D109N, N29D, N33D, Q34R, F48S, R711, D88I,
R92Q, D116A, R122A, and I133P CPs, respectively. Thirty micrograms of
extracted leaf protein was loaded in each lane.
FIG. 4. Spatial location of substituted amino acid residues in the structure of the TMV CP. (A) Lateral interactions between two subunits within the
same virion layer viewed perpendicular to the viral axis. (B) Axial interactions between two subunits located in the adjacent layers of the virion viewed
parallel to the viral axis. Black, locations of substitutions that enhanced the ability of CP to cross-protect; gray, locations of substitutions that did not
affect the ability of CP to cross-protect; and white, locations of substitutions that abolished CP cross-protection.
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two substitutions R90Q and D116A were created to in-
terfere with CP–RNA interactions. Positively charged res-
idue R90 interacts directly with a negatively charged
RNA phosphate group. Electron microscopy of TMV con-
struct R90Q revealed only disk-like aggregates (Table 1),
indicating that this substitution blocked the ability of CP
FIG. 5. The accumulation challenge TMV over time in the inoculated leaves of plants pre-infected with PVX-TMV CP constructs. Samples collected
2, 4, 6, 8, 10, and 14 days post-TMV challenge inoculations (d p.i.). TMV titer was monitored using a local lesion assay on N. tabacum cv. Xanthi nc.
Bars represent the average 6 standard deviation of the lesion numbers from 5 to 8 independent assays. 3, TMV-induced death of challenge
inoculated leaves with no further samples taken.
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to associate with viral RNA. Residue D116 interacts with
the viral RNA through its carboxylate oxygens, which
hydrogen bond with a ribose hydroxyl group and form
part of a calcium binding site with an RNA phosphate
group (Fig. 4). The D116A substitution would be expected
prevent these interactions and may also alter CP sec-
ondary structure within the RNA binding site of the inner
loop. Electron microscopy of TMV construct D116A re-
vealed the presence of both ordered disks and short
virion-like aggregates (Table 1; Fig. 2). The ability of TMV
D116A to form short helical rods suggests that this mu-
tation only partially interferes with the ability of CP to
associate with the viral RNA. However, neither CP R90Q
nor CP D116A, when expressed by the PVX vector, pro-
vided detectable levels of protection against TMV chal-
lenge inoculation (Fig. 5), indicating that interactions
between the CP and viral RNA are involved in conferring
protection.
Enhanced subunit interactions increase levels of
protection
Repulsive intersubunit carboxylate interactions be-
tween residues E50 and D77 on axially adjacent sub-
units and residues E106 and E95/E97/D109 on laterally
adjacent subunits have been shown to play an important
role in driving TMV virion disassembly (Culver, et al.,
1995; Lu et al., 1996; Fig. 4). Substitutions E50Q/D77N
and E95Q/E97Q/D109N remove the repulsive intersub-
unit charges without altering side-chain hydrogen bond-
ing patterns or hydrophobic interactions. The removal of
these repulsive intersubunit interactions enhances the
stability of the protein helix resulting in the formation of
long protein rods (Table 1; Fig. 2). These long rods have
been shown by spectroscopy to contain little viral RNA
(Lu et al., 1996). Pre-infection of N. benthamiana plants
with PVX constructs expressing CPs E50Q/D77N or
E95Q/E97Q/D109N delayed the appearance of TMV-in-
duced necrosis and accumulations for up to 4 weeks
post-challenge inoculation. This delay was twice that
observed for PVX-expressed wild-type TMV CP (Figs. 5
and 6).
DISCUSSION
A key feature of both TMV-derived cross-protection
and CPMR is that protection primarily occurs prior to the
disassembly of the challenge virus. This assumption is
supported by the ability of unencapsidated TMV RNA to
overcome both cross-protection and CPMR. Based on
this and similar findings it has been proposed that the
presence of the protecting CP blocks the disassembly of
FIG. 6. Development of TMV symptoms in N. benthamiana plants that were either systemically infected with the unmodified PVX vector (PVX2C2S)
or infected with PVX constructs expressing TMV CPs (wild-type, E50Q/D77N, or E95Q/E97Q/D109N) prior to challenge inoculation with 10 mg of TMV.
Plants represent 5–8 used per experiment. Photograph was taken at 5 weeks post-challenge inoculation. The PVX2C2S plant succumbed to
TMV-induced necrosis at 1 week post-challenge inoculation, while the CP wild-type plant collapsed at 3 weeks post-challenge inoculation.
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the challenge virus. Two mechanisms have been pro-
posed to account for the blocking of disassembly (Baw-
den and Kassanis, 1944; de Zoeten and Fulton, 1975;
Sherwood and Fulton, 1982; Register et al., 1989). The
first involves the direct recoating of the challenge virus
RNA by the protecting CP. The second predicts that the
protecting CP occupies or prevents access to a cellular
receptor or uncoating site involved in virion disassembly.
In this study, a PVX vector system was used to investi-
gate the mechanism of protection by determining the
effects of specific mutations on the ability of TMV CP to
cross-protect. These mutations were specifically de-
signed to affect virion formation, CP aggregation, or CP-
RNA interactions. The goal was to identify the structural
elements and/or aggregate capabilities of CP that were
active in conferring protection. These active features
should reflect whether the protecting CP is directly inter-
acting with challenge virus to block disassembly or if
protection is derived through an interaction with a host
receptor.
In previous studies, the ability of TMV CP to assemble
into virus-like particles was determined not to be neces-
sary to establish cross-protection (Zaitlin, 1976; Clark et
al., 1995). Specifically, an assembly deficient TMV mu-
tant, PM2, has been shown to confer transgenic CPMR
equal to that of the wild-type CP. In this study, similar
results were obtained with mutant CPs, N29D, N33D,
and Q34R, all of which fail to form full-length virions yet
still confer levels of protection similar to that of the
wild-type CP (Table 1; Fig. 5). However, mutant CPs F48S,
R71L, RI22A, and I133P also failed to form virions and yet
did not confer protection. The different abilities of these
mutant CPs to cross-protect can be explained by their
distinct abilities to form ordered aggregates. Mutant CPs
N29D, N33D, and Q34R all form helical virion-like aggre-
gates and confer protection (Fig. 2). In contrast, mutant
CPs F48S, R71L, RI22A, and I133P fail to aggregate into
to any type of ordered assembly and cannot cross-pro-
tect (Table 1; Fig. 2). Similarly, Bendahmane et al. (1997)
have determined that a TMV CP mutant incapable of
ordered aggregation does not confer CPMR. These find-
ings suggest that the TMV CP must be able to at least
partially assemble to confer protection. However, the
PM2 CP forms open helical aggregates that do not re-
semble the normal helical structure of the TMV virion
(Zaitlin and Ferris, 1964), yet it still confers CPMR (Clark
et al., 1995). This may indicate that a strict requirement
for the association of CP into virion-like aggregates is not
required for protection. Alternatively, small oligomers of
the PM2 CP may still assemble in a fashion similar to
that of the virion, and it is these small aggregates that
confer protection. Determining the precise aggregate
form(s) of CP that confers protection will require the
detailed biophysical analysis of these or similar CPs.
Interestingly, mutant CP D88I formed nonhelical or-
dered disk structures but was incapable of conferring
protection against TMV (Fig. 2 and 5). It is likely that the
D88I substitution interferes with CP–CP interactions in
such a way as to prevent subunits from overlapping in a
helical array. In comparison, CPs N29D, N33D, and Q34R
formed helical aggregates and conferred levels of pro-
tection similar to that of the wild-type CP. The inability of
CP D88I to confer protection suggests that CP’s capacity
to associate in a helical virion-like fashion is critical to its
ability to cross-protect.
The ability of CP to interact with the viral RNA was also
found to be an essential component of cross-protection.
Neither CP R92Q nor CP D116A, designed to disrupt
interactions between the CP and the viral RNA, were
capable of delaying the accumulation of TMV (Fig. 5).
However, both of these proteins self-associated into or-
dered disk or short virion-like helical aggregates (Table
1; Fig. 2). These findings suggest that the protecting CP
directly interacts with the challenge virus RNA and that
the stabilizing forces conferred by these interactions are
crucial to the ability of CP to confer protection.
Results from this study demonstrate that the capability
of CP to self-associate into virion-like helical aggregates
and to interact with the viral RNA is essential to its ability
to confer protection. These structural requirements indi-
cate that the protecting CP interacts directly with the
virion of the challenge virus to confer protection. The
association of the protecting CP with a host receptor
would seem less likely, since mutant CPs R92Q and
D116A, designed to interfere with CP-RNA interactions,
do not confer protection. Taken together, these findings
support recoating of the disassembling challenge virus
as the mechanism behind TMV CP conferred cross-
protection.
TMV disassembly is thought to involve the removal of
CP subunits from the first few turns of the RNA 59-end
leader. The removal of these subunits is likely due to a
combination of factors involving destabilization by repul-
sive intersubunit carboxylate groups (Caspar, 1963;
Namba and Stubbs, 1986; Culver et al., 1995; Lu et al.,
1996), aberrant CP–RNA interactions due to the structure
of the 7-methylguanosine RNA cap (Keith and Fraenkel-
Conrat, 1975; Zimmern, 1975), and weaker CP–RNA in-
teractions in the 59 RNA leader due to a lack of guanine
residues for which CP binds the strongest (Richards et
al., 1977; Goelet et al., 1982; Steckert and Schuster, 1982).
Together, these factors may lead to sufficient viral RNA
exposure to allow ribosomal subunits to bind, followed
by the cotranslational removal of the remaining subunits
covering the genome (Wilson, 1984). The exposure of the
RNA 59 end and the binding of ribosomes to the viral
RNA, referred to as striposomes, has been observed
both in vitro and in vivo (Wilson, 1984; Shaw et al., 1986).
However, striposome-like structures could not be iso-
lated from challenge-inoculated protoplasts derived from
transgenic CP plants (Wu et al., 1990). Furthermore, TMV
virions exposed to mild alkaline conditions, known to
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remove between 60 and 70 CP subunits or about four
helical turns from the RNA 59 end, can overcome CPMR
(Register and Beachy, 1988). This suggests that CP-de-
rived protection blocks challenge virus disassembly prior
to the binding of ribosomal subunits and the initiation of
cotranslational disassembly. Interestingly, mutant CPs
R92 and D116 make RNA contacts from opposite sides of
the subunit (Fig. 4). The fact that both R92Q and D116A
CPs fail to confer protection suggests that the protecting
CP may interact with exposed RNA from both upper and
lower subunit surfaces. These findings support a model
for protection in which a few 59 terminal subunits are
released from the challenge virus, exposing a small
number of nucleotides that are then recoated by the
protecting CP (Fig. 7).
Within the recoating model, the force predicted to drive
the reassembly of the challenge virus RNA involves a
shift in the assembly–disassembly equilibrium brought
about by the presence of the protecting CP. To test this
prediction, mutant CPs with enhanced abilities to aggre-
gate were examined for their capacity to cross-protect.
Mutant CPs E50Q/D77N and E95Q/E97Q/D109N were
designed to remove repulsive intersubunit carboxylate
interactions (Namba and Stubbs, 1986; Lu et al., 1996).
The removal of these repulsive carboxylate groups sta-
bilizes CP–CP interactions to the extent that these CPs
assemble into virion-like rods even in the absence of
viral RNA. Thus the strong affinity of these CPs to aggre-
gate should further shift the assembly–disassembly
equilibrium toward assembly. When expressed by PVX,
CPs E50Q/D77N and E95Q/E97Q/D109N delayed for up
to 5 weeks the accumulation of challenge TMV (Fig. 6;
data not shown). This delay was twice that obtained with
the wild-type CP. Bendahmane et al., (1997) have also
determined that a TMV CP mutant with increased abili-
ties to aggregate gives significantly higher levels of
CPMR as compared to the wild-type CP. Thus TMV CPs
with stronger affinities to aggregate confer significantly
higher levels of protection. These findings support a
shifting assembly–disassembly equilibrium as the mech-
anism driving the recoating of the challenge virus RNA
during cross-protection. Additionally, the use of carbox-
ylate mutant CPs or similar CPs with enhanced abilities
to aggregate also provides a useful method for improving
levels of conferred protection.
MATERIALS AND METHODS
TMV constructs and electron microscopy
Full-length infectious cDNA clones of the U1 strain of
TMV, joined to the phage SP6 promoter, pBGC150, or to
the T7 promoter, pSNC004, were used as the parental
constructs for all described mutations (Dawson et al.,
1986; Kumagai, et al., 1993; Turpen et al., 1995). Site-
directed mutagenesis was performed as previously de-
scribed (Culver et al., 1995) using the method of Geis-
selsoder et al. (1987). Each mutated TMV CP ORF was
subsequently sequenced to ensure that only the desired
mutation had been introduced. Infectious RNA was gen-
erated from each TMV construct and used to mechani-
cally inoculate leaves of N. tabacum CV. Xanthi. Infected
plant extracts, prepared by grinding 0.1 g of infected N.
tabacum cv. Xanthi tissue in 300 ml of 0.01 M phosphate
buffer, pH 7.3, at 4°C were spotted (3 ml) onto Formvar-
coated electron microscope grids and allow to dry. Grids
were then negatively stained with 1% uranyl acetate for 2
min, wicked dry with filter paper, and examined by elec-
tron microscopy.
FIG. 7. Model for the recoating of TMV challenge virus during cross-protection. The TMV 59 end consisting of CP subunits shown in ribbon form
and RNA shown in space-filling form along with exposed 59 terminal nucleotides. A single protecting CP is positioned to recoat the exposed viral RNA.
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PVX constructs and TMV CP expression
The PVX vector, pPVX2C2S (Chapman et al., 1992),
contains unique cloning sites engineered downstream of
the PVX CP subgenomic promoter. In this study, each
different TMV CP ORF was cloned as previously de-
scribed (Culver, 1996) into the EcoRV (nucleotide 5680)
and SalI (nucleotide 5684) sites of pPVX2C2S. This per-
mits the transcription and translation of the TMV CP ORF
directly from the PVX genome. The presence of each
TMV CP ORF was confirmed by DNA sequencing.
Infectious RNA transcripts were subsequently gener-
ated from each PVX construct and used to inoculate
leaves of N. benthamiana (Chapman et al., 1992). PVX
vector-infected tissue was extracted, and total protein
concentrations determined by Bradford assay (Bradford,
1976). The extracted proteins were resolved by SDS–
PAGE (Laemmli, 1970) and electro-blotted onto nitrocel-
lulose paper followed by Western immunodetection for
the presence of TMV CP (Lehto et al., 1990).
Cross-protection assays
Infectious PVX transcripts were directly inoculated
onto N. benthamiana plants at the three- to four-leaf
stage. Inoculated plants were maintained in environmen-
tal growth chambers at 25°C under a 12-h photoperiod.
The first two leaves of each plant to show systemic
mild-mosaic PVX symptoms were subsequently dusted
with Carborundum and challenge inoculated with 5 mg of
purified TMV in phosphate buffer, pH 7.4. Plants were
monitored for both the development of TMV-induced ne-
crotic symptoms as well as the accumulations of TMV. To
assay the accumulation of TMV, plant samples, two
0.5-cm leaf punches, were taken from each of the two
challenge inoculated leaves at 2, 4, 6, 8, 10, and 14 d p.i.
or until the plants succumbed to necrosis. The leaf
punches (0.1 g) were ground in 100 ml of 10 mM sodium
phosphate buffer, pH 7.4, and 20 ml used to inoculated a
leaf of N. tabacum cv Xanthi-nc, a local lesion host for
TMV but not for PVX. Lesion numbers, representing the
accumulation of challenge TMV, were recorded after 4
days.
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